Delcath Systems, Inc. (DCTH)
NASDAQ: DCTH · Real-Time Price · USD
9.08
-0.44 (-4.62%)
Nov 4, 2025, 4:00 PM EST - Market closed
Delcath Systems Employees
Delcath Systems had 96 employees as of December 31, 2024. The number of employees increased by 20 or 26.32% compared to the previous year.
Employees
96
Change (1Y)
20
Growth (1Y)
26.32%
Revenue / Employee
$829,198
Profits / Employee
$12,479
Market Cap
317.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 96 | 20 | 26.32% |
| Dec 31, 2023 | 76 | 24 | 46.15% |
| Dec 31, 2022 | 52 | -3 | -5.45% |
| Dec 31, 2021 | 55 | 19 | 52.78% |
| Dec 31, 2020 | 36 | 3 | 9.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DCTH News
- 12 hours ago - Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 hours ago - Delcath Systems Reports Third Quarter 2025 Results and Business Highlights - Business Wire
- 14 days ago - Delcath Systems to Host Third Quarter 2025 Earnings Call - Business Wire
- 15 days ago - Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript - Seeking Alpha
- 15 days ago - Delcath: Large Upside With Limited Downside Risk - Seeking Alpha
- 17 days ago - Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results - Business Wire
- 17 days ago - Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint - Business Wire
- 6 weeks ago - Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress - Business Wire